Therapies for Chronic Allograft Rejection.

Area of Science:

• Nephrology
• Transplant Immunology
• Immunopathology

Background:

• Antibody-mediated rejection (ABMR) significantly impacts long-term graft survival despite advances in diagnosis and treatment.
• Chronic ABMR, characterized by slow progression and de novo donor-specific antibodies (DSA), presents unique challenges distinct from active ABMR.
• Current immunosuppressive therapies, primarily developed for active ABMR, show limited efficacy in managing chronic ABMR.

Purpose of the Study:

• To review the pathophysiology and characteristics of chronic ABMR.
• To analyze the reasons for the limited effectiveness of current immunosuppressive therapies in chronic ABMR.
• To explore emerging research and non-invasive biomarkers for future treatment strategies and monitoring of chronic ABMR.

Main Methods:

• In-depth literature review focusing on chronic ABMR.
• Analysis of the 2017 Banff criteria relevant to chronic ABMR.
• Examination of current research on immunosuppressive therapy resistance and novel therapeutic approaches.

Main Results:

• Chronic ABMR is a distinct entity from active ABMR, driven by de novo DSA and characterized by slow graft injury.
• Existing treatment strategies for active ABMR are often insufficient for chronic ABMR due to differingPathophysiology.
• Understanding the mechanisms of immunosuppressive resistance is key to developing effective interventions.

Conclusions:

• Effective treatments for chronic ABMR are urgently needed to improve long-term graft survival.
• Further research into the unique pathophysiology of chronic ABMR is essential for targeted therapeutic development.
• Non-invasive biomarkers hold promise for monitoring rejection and guiding future treatment strategies.